Promethium Advisors LLC Raises Position in Johnson & Johnson $JNJ

Key Points

• Promethium Advisors LLC increased its stake in Johnson & Johnson by 14.5%, making it the firm's 8th largest position, with a total investment valued at approximately $3.79 million.
• Johnson & Johnson reported $2.77 earnings per share for the most recent quarter, exceeding analysts' expectations, and set its fiscal year 2025 guidance at 10.800-10.900 EPS.
• The company announced a quarterly dividend of $1.30 per share, yielding 2.9%, and plans to distribute this on September 9th to shareholders recorded by August 26th.

Promethium Advisors LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 14.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,864 shares of the company's stock after purchasing an additional 2,902 shares during the period. Johnson & Johnson accounts for 2.4% of Promethium Advisors LLC's holdings, making the stock its 8th biggest position. Promethium Advisors LLC's holdings in Johnson & Johnson were worth $3,792,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. Federation des caisses Desjardins du Quebec grew its holdings in Johnson & Johnson by 3.4% in the 1st quarter. Federation des caisses Desjardins du Quebec now owns 727,077 shares of the company's stock valued at $120,580,000 after buying an additional 23,892 shares in the last quarter. EP Wealth Advisors LLC raised its position in Johnson & Johnson by 3.4% in the first quarter. EP Wealth Advisors LLC now owns 562,576 shares of the company's stock valued at $93,298,000 after purchasing an additional 18,238 shares during the last quarter. Ashton Thomas Securities LLC raised its position in Johnson & Johnson by 23.7% in the first quarter. Ashton Thomas Securities LLC now owns 2,802 shares of the company's stock valued at $464,000 after purchasing an additional 537 shares during the last quarter. GW Henssler & Associates Ltd. raised its position in shares of Johnson & Johnson by 40.7% during the first quarter. GW Henssler & Associates Ltd. now owns 3,657 shares of the company's stock worth $606,000 after acquiring an additional 1,058 shares during the last quarter. Finally, Capital Investment Counsel LLC acquired a new stake in Johnson & Johnson during the first quarter worth approximately $225,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

NYSE:JNJ traded up $0.64 on Thursday, reaching $178.64. 7,798,607 shares of the company's stock traded hands, compared to its average volume of 8,965,323. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a 50-day simple moving average of $167.53 and a 200-day simple moving average of $160.45. The firm has a market cap of $430.23 billion, a PE ratio of 19.11, a P/E/G ratio of 2.26 and a beta of 0.40. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period last year, the firm earned $2.82 earnings per share. The business's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research reports. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Barclays increased their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Finally, Morgan Stanley increased their target price on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.